Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dick de Zeeuw

Showing results (21-30 of 394) with videos related to

Pageof 40
Sort By:
Kidney International|November 27, 2014
The authors replyDick de Zeeuw, Mark E Molitch
Nature Clinical Practice. Cardiovascular Medicine|July 17, 2008
Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease?Dick de Zeeuw, Stephan Jl Bakker
The Lancet. Diabetes & Endocrinology|August 16, 2014
Do diabetic kidneys deserve a lifestyle change?Dick de Zeeuw, Hiddo Lambers Heerspink
The New England Journal of Medicine|May 3, 2014
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney diseaseGlenn M Chertow, Dick de Zeeuw,
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2022
Endothelin Receptor Antagonists for Kidney Protection: Lessons from the SONAR TrialHiddo J L Heerspink, Dick de Zeeuw
Diabetes, Obesity & Metabolism|October 9, 2018
Treating diabetic complications; from large randomized clinical trials to precision medicineHiddo J L Heerspink, Dick de Zeeuw
Journal of the American Society of Nephrology : JASN|June 14, 2014
Are post-trial observational studies useful?Hiddo J Lambers Heerspink, Dick de Zeeuw
Diabetologia|June 25, 2016
Novel anti-inflammatory drugs for the treatment of diabetic kidney diseaseHiddo J L Heerspink, Dick De Zeeuw
Journal of the American Society of Nephrology : JASN|December 6, 2002
Renoprotection: a matter of blood pressure reduction or agent-characteristics?Liffert Vogt, Gerjan Navis, Dick de Zeeuw
American Journal of Nephrology|April 24, 2010
Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?Hiddo J Lambers Heerspink, Dick de Zeeuw
Pageof 40

Showing results (21-30 of 394) with videos related to

Sort By:
Pageof 40
Kidney International|November 27, 2014
The authors replyDick de Zeeuw, Mark E Molitch
Nature Clinical Practice. Cardiovascular Medicine|July 17, 2008
Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease?Dick de Zeeuw, Stephan Jl Bakker
The Lancet. Diabetes & Endocrinology|August 16, 2014
Do diabetic kidneys deserve a lifestyle change?Dick de Zeeuw, Hiddo Lambers Heerspink
The New England Journal of Medicine|May 3, 2014
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney diseaseGlenn M Chertow, Dick de Zeeuw,
Clinical Journal of the American Society of Nephrology : CJASN|April 28, 2022
Endothelin Receptor Antagonists for Kidney Protection: Lessons from the SONAR TrialHiddo J L Heerspink, Dick de Zeeuw
Diabetes, Obesity & Metabolism|October 9, 2018
Treating diabetic complications; from large randomized clinical trials to precision medicineHiddo J L Heerspink, Dick de Zeeuw
Journal of the American Society of Nephrology : JASN|June 14, 2014
Are post-trial observational studies useful?Hiddo J Lambers Heerspink, Dick de Zeeuw
Diabetologia|June 25, 2016
Novel anti-inflammatory drugs for the treatment of diabetic kidney diseaseHiddo J L Heerspink, Dick De Zeeuw
Journal of the American Society of Nephrology : JASN|December 6, 2002
Renoprotection: a matter of blood pressure reduction or agent-characteristics?Liffert Vogt, Gerjan Navis, Dick de Zeeuw
American Journal of Nephrology|April 24, 2010
Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?Hiddo J Lambers Heerspink, Dick de Zeeuw
Pageof 40